Jacob Pendergrast

Jacob Pendergrast


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2021 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CPChristopher J. Patriquin
Christopher J. Patriquin
VLVincent Laroche
Vincent Laroche
RSRita Selby
Rita Selby
JPJacob Pendergrast
Jacob Pendergrast
DBDavid Barth
David Barth
JMJohnathan P. Mack
Johnathan P. Mack
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is characterized by thrombosis and thrombocytopenia that occurs 5 to 30 days after ChAdOx1 nCoV-19 vaccination and is associated with heparin-independent platelet factor 4 (PF4) antibodies.1-3 Mortality from VITT is approximately 30 to 60%.1-3 PF4 enzyme-linked immunosorbent assays (ELISAs) in the absence of heparin may be diagnostic; however, functional testing (e.g., serotonin release assay with added PF4 [PF4 SRA]) is recommended.1-4 Initial treatment includes nonheparin anticoagulation and high-dose intravenous immune globulin (IVIG). The treatment that should be used for patients with VITT that does not respond to initial treatment remains unclear.


14 July 2015 in Transfusion
Verified
Journal Article
Closed access
PDF file
JPJacob Pendergrast
Jacob Pendergrast
KWKezia Willie‐Ramharack
Kezia Willie‐Ramharack
LSLorna Sampson
Lorna Sampson
VLVincent Laroche
Vincent Laroche
DBDonald R. Branch
Donald R. Branch

12 January 2021 in Transfusion
Verified
Journal Article
Closed access
PDF file
JPJacob Pendergrast
Jacob Pendergrast
CAChantal Armali
Chantal Armali
JCJeannie Callum
Jeannie Callum
CCChristine Cserti-Gazdewich
Christine Cserti-Gazdewich
AJAziz Jiwajee
Aziz Jiwajee
TPThe QUEST Research Program
The QUEST Research Program

28 March 2019 in Transfusion
Verified
Journal Article
Closed access
PDF file
JPJacob Pendergrast
Jacob Pendergrast
CAChantal Armali
Chantal Armali
CCChristine Cserti-Gazdewich
Christine Cserti-Gazdewich
MHMark Hansen
Mark Hansen
AKAlex Kiss
Alex Kiss
YLYulia Lin
Yulia Lin

1 July 2023 in CMAJ Open
Verified
Journal Article
Open access
PDF file
JPJacob Pendergrast
Jacob Pendergrast
LALanre Tunji Ajayi
Lanre Tunji Ajayi
EKEliane Kim
Eliane Kim
MCMichael A. Campitelli
Michael A. Campitelli
EGErin Graves
Erin Graves
Background: The number of patients with sickle cell disease in Ontario, Canada, is unknown. In the absence of a formal registry, we performed a study to determine an approximate census via analysis of health administrative databases. Methods: We identified Ontario patients with a diagnosis of sickle cell disease through queries of the Discharge Abstract Database, National Ambulatory Care Reporting System and Newborn Screening Ontario database. The period of inquiry was Apr. 1, 2007, through Mar. 31, 2017. We identified repeat interactions by the same patient by cross-referencing provincial health insurance plan numbers. Results: We documented health care system interactions for 3418 unique patients (1912 [55.9%] female, median age at the time of identification 24 yr). Over the 10-year study period, patients visited the emergency department a median of 2 (interquartile range [IQR] 1–7) times and an average of 6.69 (standard deviation [SD] 26.71) times, and were admitted to hospital a median of 1 (IQR 1–5) time and an average of 4.38 (SD 8.53) times for treatment related to sickle cell disease. A total of 229 patients (6.7%) died during the study period, with an average age at death of 55 years. Even without accounting for the effects of immigration, the rate of natural increase slowed slightly over the study period owing to a decrease in the annual number of affected births. Interpretation: The estimated prevalence of patients with sickle cell disease in Ontario in 2007/08–2016/17 was 1 in 4200, and affected patients’ need for hospital-based care was substantial, although highly variable. Similar queries of health administrative databases may be feasible in other Canadian provinces.